Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 7 January 2022, including: new mRNA deal for Pfizer Inc. and BioNTech SE; court ruling helps Novartis AG’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio Pharma, Inc.’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Beximco Delivers First Cut-Price Generic Paxlovid" - Scrip, 31 Dec, 2021.)
(Also see "Stock Watch: Bridgebio’s Endpoint A Bridge Too Far" - Scrip, 3 Jan, 2022.)
(Also see "Gene-Editing Companies To Watch At J.P. Morgan" - Scrip, 5 Jan, 2022.)